CD4+ and CD8+ CD28null T Cells Are Cytotoxic to Autologous Muscle Cells in Patients With Polymyositis

Arthritis and Rheumatology

Volumn 68, Issue 8, 2016, Pages 2016-2026

  Pandya, Jayesh M ^a   Venalis, Paulius ^a   Al Khalili, Lubna ^b   Shahadat Hossain, Mohammad ^a   Stache, Vanessa ^a   Lundberg, Ingrid E ^a   Malmström, Vivianne ^a   Fasth, Andreas E R ^c,d,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Schering Plough   (United States)

^e NOVARTIS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCEIN; CONCANAMYCIN A; GAMMA INTERFERON; GRANZYME B; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; PERFORIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CASE REPORT; CD28+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL STRUCTURE; COCULTURE; CYTOTOXICITY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; MIDDLE AGED; MYOBLAST; MYOTUBE; POLARIZATION; POLYMYOSITIS; PRIORITY JOURNAL; SKELETAL MUSCLE CELL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; VERY ELDERLY;

EID: 84979498458     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39650     Document Type: Article

References (48)

1. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193–208.
2. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16:209–15.
3. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V. Identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol 1988;23:493–9.
4. Orimo S, Koga R, Goto K, Nakamura K, Arai M, Tamaki M, et al. Immunohistochemical analysis of perforin and granzyme A in inflammatory myopathies. Neuromuscul Disord 1994;4:219–26.
5. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905–10.
6. Sugihara T, Okiyama N, Suzuki M, Kohyama K, Matsumoto Y, Miyasaka N, et al. Definitive engagement of cytotoxic CD8 T cells in C protein–induced myositis, a murine model of polymyositis. Arthritis Rheum 2010;62:3088–92.
7. null T cells. J Immunol 2009;183:4792–9.
8. Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfeld R. T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J Exp Med 1995;181:1863–8.
9. Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, Simoncini O, et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis: restricted V α/β rearrangements may indicate antigen-driven selection. J Clin Invest 1993;91:2880–6.
10. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011;7:297–306.
11. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980;92:365–9.
12. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1α, interleukin-1β, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000;43:336–48.
13. Korotkova M, Helmers SB, Loell I, Alexanderson H, Grundtman C, Dorph C, et al. Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 2008;67:1596–602.
14. null T cells are associated with defects in apoptotic pathways. J Immunol 2000;165:6301–7.
15. − T cells: their role in the age-associated decline of immune function. Trends Immunol 2009;30:306–12.
16. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 1998;41:2108–16.
17. + T cells: characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol 2004;60:199–208.
18. null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol 2007;179:6514–23.
19. Pandya JM, Loell I, Hossain MS, Zong M, Alexanderson H, Raghavan S, et al. Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis. Arthritis Res Ther 2016;18:80.
20. − T cells from rheumatoid arthritis patients. J Immunol 1998;161:1018–25.
21. null T cells resistant to apoptosis in acute coronary syndrome. Circulation 2015;131:709–20.
22. Snyder MR, Nakajima T, Leibson PJ, Weyand CM, Goronzy JJ. Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J Immunol 2004;173:3725–31.
23. − T cells in patients with rheumatoid arthritis. Eur J Immunol 2010;40:378–87.
24. Hodge G, Jersmann H, Tran HB, Holmes M, Reynolds PN, Hodge S. Lymphocyte senescence in COPD is associated with loss of glucocorticoid receptor expression by pro-inflammatory/cytotoxic lymphocytes. Respir Res 2015;16:2.
25. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7.
26. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403–7.
27. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996;156:3678–86.
28. Liuzzo G, Kopecky SL, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100:2135–9.
29. null cells in COPD: implications of autoimmunity. Wien Klin Wochenschr 2013;125:150–5.
30. Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbar A, Af Klint E, et al. Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis. Arthritis Res Ther 2007;9:R87.
31. Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991;29:498–507.
32. Xiao R, Ferry AL, Dupont-Versteegden EE. Cell death-resistance of differentiated myotubes is associated with enhanced anti-apoptotic mechanisms compared to myoblasts. Apoptosis 2011;16:221–34.
33. Salucci S, Burattini S, Baldassarri V, Battistelli M, Canonico B, Valmori A, et al. The peculiar apoptotic behavior of skeletal muscle cells. Histol Histopathol 2013;28:1073–87.
34. Owens J, Moreira K, Bain G. Characterization of primary human skeletal muscle cells from multiple commercial sources. In Vitro Cell Dev Biol Anim 2013;49:695–705.
35. Nemoto H, Bhopale MK, Constantinescu CS, Schotland D, Rostami A. Skeletal muscle myosin is the autoantigen for experimental autoimmune myositis. Exp Mol Pathol 2003;74:238–43.
36. Allenbach Y, Solly S, Gregoire S, Dubourg O, Salomon B, Butler-Browne G, et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol 2009;174:989–98.
37. Matsubara S, Okumura S. Experimental autoimmune myositis in SJL/J mice produced by immunization with syngeneic myosin B fraction: transfer by both immunoglobulin G and T cells. J Neurol Sci 1996;144:171–5.
38. Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001;124:282–9.
39. Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001;159:1263–73.
40. Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-1α expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 2002;46:1044–55.
41. null T cells. Arthritis Rheum 2010;62:3457–66.
42. null T cells clonally expanded in rheumatoid arthritis. J Immunol 2000;165:1138–45.
43. − T cells in healthy ageing people, including centenarians. Immunology 1996;88:501–7.
44. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002;105:570–5.
45. Scheler M, Irmler M, Lehr S, Hartwig S, Staiger H, Al-Hasani H, et al. Cytokine response of primary human myotubes in an in vitro exercise model. Am J Physiol Cell Physiol 2013;305:C877–86.
46. Ritter M, Huber C, Aubock J, Pohl-Markl H, Troppmair J, Herold M, et al. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status. Immunology 1994;81:569–77.
47. Nakajima T, Goek O, Zhang X, Kopecky SL, Frye RL, Goronzy JJ, et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ Res 2003;93:106–13.
48. null T cells in bronchiolitis obliterans syndrome. Clin Exp Immunol 2013;173:150–60.